Pharmacogenomic Testing in Patients with Hand-Foot Skin Reaction on Tyrosine Kinase Inhibitors


About this study

The purpose of this research study is to:

  • Find out whether there are any DNA (genetic) changes and mutations that put you at risk of developing this skin reaction and use that information to predict the side effect on patients with similar results in the future.

  • Help us better manage the hand-foot skin reaction if it develops by recommending the appropriate treatment

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients will be recruited from the cancer center at Mayo Clinic Arizona and Rochester.
  • Eligibility requires patients with age ≥ 18 years old.
  • Able to give informed consent.
  • Having a malignancy that is currently treated with one of the listed oral TKIs.
    • The TKIs that are being studied are the following: axitinib, cabozantinib, lenvatinib, pazopanib, regorafenib, sorafenib, and sunitinib.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Mohamad Sonbol, M.D.

Closed for enrollment

Contact information:

Eric Yancey Pharm.D., R.Ph., BCOP

(480) 342-4800

More information


Publications are currently not available

Mayo Clinic Footer